Latest news with #BoobalanPachaiyappan
Business Insider
3 days ago
- Business
- Business Insider
Roth MKM Keeps Their Buy Rating on Capricor Therapeutics (CAPR)
In a report released yesterday, Boobalan Pachaiyappan from Roth MKM reiterated a Buy rating on Capricor Therapeutics (CAPR – Research Report), with a price target of $31.00. The company's shares closed yesterday at $13.14. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Pachaiyappan is an analyst with an average return of -7.9% and a 36.71% success rate. Pachaiyappan covers the Healthcare sector, focusing on stocks such as Cingulate Inc, Gain Therapeutics, and CervoMed. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Capricor Therapeutics with a $41.50 average price target, which is a 215.83% upside from current levels. In a report released yesterday, Oppenheimer also reiterated a Buy rating on the stock with a $43.00 price target.
Business Insider
20-05-2025
- Business
- Business Insider
Roth MKM Sticks to Its Buy Rating for Reviva Pharmaceuticals Holdings (RVPH)
In a report released yesterday, Boobalan Pachaiyappan from Roth MKM reiterated a Buy rating on Reviva Pharmaceuticals Holdings (RVPH – Research Report), with a price target of $7.00. The company's shares closed yesterday at $0.89. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter According to TipRanks, Pachaiyappan is an analyst with an average return of -9.8% and a 31.51% success rate. Pachaiyappan covers the Healthcare sector, focusing on stocks such as Cingulate Inc, Gain Therapeutics, and CervoMed. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Reviva Pharmaceuticals Holdings with a $10.00 average price target, representing a 1,023.60% upside. In a report released on May 16, Maxim Group also maintained a Buy rating on the stock with a $5.00 price target. The company has a one-year high of $4.28 and a one-year low of $0.49. Currently, Reviva Pharmaceuticals Holdings has an average volume of 757.6K.
Business Insider
19-05-2025
- Business
- Business Insider
Cingulate price target lowered to $11 from $12 at Roth Capital
Roth Capital analyst Boobalan Pachaiyappan lowered the firm's price target on Cingulate (CING) to $11 from $12 and keeps a Buy rating on the shares post the Q1 report. The firm says its discussions with management further bolstered its conviction for CTx-1301 application filing, which it expects to occur in Q3. Roth's base case assumes CTx-1301 FDA approval by Q4 of 2026 and launch by the first half of 2027. Confident Investing Starts Here:
